ArticleInfection and drug resistance2022
Factors Affect the Eradication Rate of
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Factors related to loss to follow-up and low compliance in Helicobacter pylori-infected children: The EuroPedHp Registry.Journal of pediatric gastroenterology and nutrition · 2026Observational
- Impact of kimura-takemoto atrophy classification on first-lineFrontiers in medicine · 2026Article
- Efficacy of Vonoprazan-Doxycycline Dual Therapy for the Treatment ofInfection and drug resistance · 2026Article
- No significant link found between Helicobacter pylori serological antibodies and the development of esophageal adenocarcinoma.Discover oncology · 2025Article
- Biomaterials mediated 3R (remove-remodel-repair) strategy: holistic management of Helicobacter pylori infection.Journal of nanobiotechnology · 2025Review
- Analysis of the status and risk factors for Helicobacter pylori infection and drug resistance in the Lianyungang area, China.BMC gastroenterology · 2025Article
- Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management.United European gastroenterology journal · 2024Article
- Clarithromycin sustained-release tablet may be an improper therapy for the eradication ofTherapeutic advances in gastroenterology · 2024Article
- Knowledge, Attitude, and Practice of the Gastroenterology Department Patients Towards Chronic Gastritis in Shanxi Region: A Cross-Sectional Study.Patient preference and adherence · 2024Article
- Vitamin D and Its Association withNutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate related factors affecting the eradication rate of Methods: Between September 2020 and March 2021, 341 patients who were diagnosed with Hp infection and whose infections were confirmed by gastroscopy, a histological examination, and a C13-UBT without culturing and antimicrobial susceptibility studies received a two-week anti-Hp treatment, a modified quadruple therapy, in our department. The result of C13-UBT was rechecked 4 weeks after the drug withdrawal, and the patients were divided into two groups-a success group and a failure group-according to the final breath result. The general clinical information and related laboratory indexes of each patient were collected, and the factors affecting the eradication rate were analyzed. Results: The total clinical eradication rate was 80.06% (273/341), and the failure rate was 19.94% (68/341), correspondingly. Univariate analysis identified statistically significant differences between the two groups in serum 25-hydroxyvitamin D levels, presence of oral diseases, positive cytotoxin-associated gene A (CagA), and medical compliance ( Conclusion: Serum 25-hydroxyvitamin D level lower than 20 ng/mL may affect the success of eradication of Hp and is an independent risk factor for eradication failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.